Arcus Biosciences Inc RCUS.N, RCUS.K is expected to show a fall in quarterly revenue when it reports results on February 25 for the period ending December 31 2024
The Hayward California-based company is expected to report a 6.8% decrease in revenue to $28.9 million from $31 million a year ago, according to the mean estimate from 10 analysts, based on LSEG data.The company's guidance on November 6 2024, for the period ended December 31, was for revenue of $30.000 million.
LSEG's mean analyst estimate for Arcus Biosciences Inc is for a loss of $1.25 per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy," 3 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Arcus Biosciences Inc is $29.00, above its last closing price of $11.07.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Sep. 30 2024 | -1.03 | -1.06 | -1.00 | Beat | 5.9 |
Jun. 30 2024 | -1.12 | -1.10 | -1.02 | Beat | 7.1 |
Mar. 31 2024 | -1.02 | -0.95 | -0.05 | Beat | 94.7 |
Dec. 31 2023 | -1.00 | -1.02 | -1.08 | Missed | -5.5 |
Sep. 30 2023 | -1.12 | -1.13 | -0.94 | Beat | 16.7 |
Jun. 30 2023 | -1.09 | -1.10 | -1.04 | Beat | 5.3 |
Mar. 31 2023 | -1.17 | -1.16 | -1.09 | Beat | 6.3 |
Dec. 31 2022 | -1.02 | -1.07 | -0.93 | Beat | 12.8 |
This summary was machine generated February 21 at 22:24 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。